证券日报网讯 1月5日，迪安诊断发布公告称，公司于2025年12月31日召开职工代表大会，经与会职工 代表表决，选举刘洋女士担任公司第五届董事会职工代表董事，任期自职工代表大会选举通过之日起至 第五届董事会届满之日（2026年11月3日）止。 （文章来源：证券日报） ...

证券日报网讯 1月5日，迪安诊断发布公告称，控股股东陈海斌将所持1736万股公司股份质押续期至 2026年6月30日，占其持股10.56%，对应公司总股本2.78%，质权人为招商证券股份有限公司。 （文章来源：证券日报） ...

证券代码：300244 证券简称：迪安诊断 公告编号：2026-001 迪安诊断技术集团股份有限公司 关于控股股东部分股份质押续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于近日接到公司控股 股东陈海斌先生通知，获悉其将持有的公司部分股份办理了质押续期，相关手续 已办理完毕。具体事项如下： 一、股东股份本次质押续期的基本情况 本次股份质押为控股股东陈海斌先生对前期股份质押的续期，不涉及新增融 资，具体情况如下： | 股东 | 是否为控 股股东或 | 本次质 | 占其所 | 占公司 | 是否 | 是否为 | 质押 | 质押 | 续期 后质 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 第一大股 | 押数量 | 持股份 | 总股本 | 为限 | 补充质 | 起始 | 到期 | | 质权人 | 质押 用途 | | | 东及其一 | （万股） | 比例 | 比例 | 售股 | 押 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Insights - The recent issuance of the "Guidelines for the Pricing of Pathology Medical Services" marks a new phase of standardization, normalization, and digital collaboration in China's pathology medical services [4] - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of digital slices, remote diagnosis, and intelligent analysis, which is expected to accelerate the digital transformation of the pathology discipline [4] - The refined pricing model is anticipated to enhance the medical pricing management system and incentivize medical institutions to invest in standardized construction and technological innovation in pathology services [4] Summary by Relevant Sections Industry Overview - The closing index is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Beneficiary Companies - Beneficiary companies include: - Anbiping, which has achieved full automation in specimen preparation, staining, and scanning, aligning with digital slice application requirements [5] - Aidesheng, focusing on core diagnostic solutions for various cancers with an automated reporting and data management system [5] - Zhongyuan Qihe, specializing in diagnostics for major diseases, providing comprehensive solutions through a combination of equipment, reagents, and services [5] - Maike Biology, which offers solutions for pathology diagnosis automation and intelligence [5] - Other notable companies in the ICL category include Jinyu Medical, Dean Diagnosis, Lanwei Medical, and Aidekang [5]

Core Insights - The National Healthcare Security Administration has officially issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)" which marks a new phase of standardized, regulated, and digital collaborative development in China's pathology medical services [1][2] Group 1: Policy Overview - The guidelines consolidate existing pathology medical service pricing projects into 28 core items, 3 additional charge items, and 2 expansion items, creating a clearer pricing framework [2] - The National Healthcare Security Administration will guide provinces to establish a unified price benchmark, allowing regions to adjust actual execution prices based on this benchmark [2] Group 2: Digital Transformation - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of new service models such as digital slides, remote diagnosis, and intelligent analysis [3] - This shift is expected to accelerate the transition of pathology from traditional manual operations to a fully digital process, making pathology data an important "data asset" in medical services [3] Group 3: Beneficiary Companies - Companies like Anbiping, which has automated workstations for specimen processing and supports digital slide applications, are well-positioned to benefit from this policy [4] - Aide Biology focuses on precision medical conditions and has developed an automated reporting and data management system, enhancing its capabilities in pathology services [4] - Zhongyuan Qihua provides comprehensive solutions for major diseases, integrating equipment, reagents, and services to support clinical medical institutions [4] - Maike Biology specializes in providing reagents, equipment, and technical support for pathology diagnosis, aiming for automation and intelligence in laboratory processes [4] - Other companies in the ICL category include Jinyu Medical, Dean Diagnostics, Lanwei Medical, and Aide Kang, which are also expected to benefit from the policy [4]

证券代码：300244 证券简称：迪安诊断 公告编号：2026-002 迪安诊断技术集团股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2026 年 1 月 5 日 附件：公司第五届董事会职工代表董事简历 刘洋，女，1981 年出生，中国国籍，无境外永久居留权。2004 年 7 月加入公司，历任 ICL 质量管理部总监、ICL 质量管理部总经理、实验室 管理中心兼交付中心常务副总经理等职务；2020 年 9 月至 2023 年 11 月 曾任公司职工代表监事。 截至本公告披露日，刘洋女士持有公司 13,400 股股份，与公司控股 股东、实际控制人、持股 5%以上股份的股东及公司董事、高级管理人员 不存在关联关系。未受到中国证监会及其他有关部门的处罚和证券交易所 任何惩戒，不存在《公司法》和《公司章程》规定的不得担任公司职工代 表董事的情形，亦不是失信被执行人，符合有关法律、行政法规、部门规 章及规范性文件等要求的任职资格。 迪安诊断技术集团股份有限公司（以下简称"公司"）于2025年12月31日召开 ...

Core Viewpoint - The divorce between the actual controller of Shichuang Energy, Fu Liming, and Wang Yanxiao has resulted in a significant financial settlement, impacting the company's shareholding structure but not its control [1][4]. Group 1: Divorce Settlement - Fu Liming and Wang Yanxiao's divorce will involve a financial settlement of approximately 450 million yuan, based on the closing price on the announcement date [2][3]. - The divorce agreement includes the transfer of Fu Liming's indirect holdings in Shichuang Energy, totaling about 34.16 million shares, which represents approximately 8.54% of the company's total share capital [2][4]. Group 2: Company Performance - Shichuang Energy reported a net loss of 649 million yuan in 2024 and a net loss of 254 million yuan in the first three quarters of 2025, indicating ongoing financial challenges [2][11]. - The company's revenue for 2023 was 1.731 billion yuan, a decrease of 27.74% year-on-year, while the revenue for 2024 dropped to 711 million yuan, a decline of 58.93% [11]. - In the first three quarters of 2025, Shichuang Energy's revenue increased by 54.30% year-on-year to 705 million yuan, although it still reported a net loss [11]. Group 3: Shareholding Structure - Despite the divorce, Fu Liming remains the actual controller of Shichuang Energy, holding significant voting rights through his investments in Shichuang Investment and Nanjing Sicheng [4][12]. - Post-divorce, Fu Liming will still control approximately 70.04% of the voting rights in the company, ensuring no change in the company's governance structure [4][12]. Group 4: Employee and Market Dynamics - The company has seen a reduction in employee numbers, with a net decrease of 238 employees, approximately 17%, since its IPO [12]. - As of December 31, 2025, Shichuang Energy's stock price was 13.9 yuan per share, significantly lower than its initial offering price of 19.20 yuan and the opening price of 29.99 yuan [12][13].

Group 1 - The article discusses the trend of investment banking professionals, particularly women, marrying into wealthy families and the financial implications of such unions [1][11][26] - A recent high-profile divorce involved Wang Yanxiao, who received approximately 4.46 billion yuan worth of shares from Shichuang Energy as part of the settlement [2][7][9] - Since 2020, there have been 34 instances of high-value divorces among A-share controlling shareholders, with a total of 764.44 billion yuan distributed to their spouses [2][3] Group 2 - Wang Yanxiao has a strong professional background, having worked at CITIC Securities and served as a board secretary for a listed company, showcasing the capabilities of "investment banking women" [5][7] - The divorce settlement included Wang receiving 34,161,801 shares, representing 8.54% of Shichuang Energy's total share capital, while the controlling shareholder, Fu Liming, retains significant control over the company [7][8][9] - The article highlights the increasing visibility and influence of women from investment banking backgrounds in high-net-worth relationships, emphasizing their dual roles in both personal and professional spheres [1][11][26]

北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的 法律意见书 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310016 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的法律意见书 北京德恒（杭州）律师事务所 德恒【杭】书（2025）第 12073 号 致：迪安诊断技术集团股份有限公司 迪安诊断技术集团股份有限公司（下称"公司"）2025 年第一次临时股东 大会（下称"本次股东大会"）于 2025 年 12 月 31 日（星期三）14:30 在杭州市 西湖区三墩镇金蓬街 329 号召开。北京德恒（杭州）律师事务所（下称"本所"） 受公司委托，指派本所律师出席本次股东大会。根据《中华人民共和国公司法》 （下称"《公司法》"）《上市公司股东大会规则》（下称"《股东大会规则》"） 等相关法律、法规、规范性文件以及《迪安诊断技术集团股份有限公司章程》（下 称"《公司章程》"）和《迪安诊断技术集团股份有限公司股东大会议事规 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-044 迪安诊断技术集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 （1）现场会议时间：2025 年 12 月 31 日（星期三）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 12 月 31 日 9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交 易所互联网投票系统的具体时间为：2025 年 12 月 31 日 9:15-15:00。 2、会议召开地点：杭州市西湖区三墩镇金蓬街 329 号。 3、会议召开方式：本次股东大会以现场投票与网络投票相结合的方式召开。 4、会议召集人：公司董事会。 5、会议主持人：陈海斌先生。 6、会议出席情况： 二、议案审议情况 本次股东大会采取现场记名投票与网络投票表决相结合的方式 ...